Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060801 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT00060801 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 420 participants.
The verdict
NCT00060801, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of 24 weeks of treatment with BIIL 284 BS compared with placebo on pulmonary function and incidence of pulmonary exacerbation in adult and pediatric cystic fibrosis patients.
Interventions
- DRUG BIIL 283 BS (Amelubent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060801
The ClinicalTrials.gov registry entry for NCT00060801 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIL 283 BS (Amelubent) is the first listed.
NCT00060801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060801 about?
NCT00060801 is a clinical study titled "Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients". The purpose of this study is to determine the effect of 24 weeks of treatment with BIIL 284 BS compared with placebo on pulmonary function and incidence of pulmonary exacerbation in adult and pediatric cystic fibrosis patients.
What is the current status of trial NCT00060801?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2003-05.
What interventions are being tested in trial NCT00060801?
The interventions under investigation include: BIIL 283 BS (Amelubent) (DRUG).
Who is sponsoring clinical trial NCT00060801?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.